文献速递肝胆胰外科围术期管理与 ERAS

术前ERCP支架置入不增加胰十二指肠切除术后并发症风险:ACS-NSQIP分析

Pre-operative stenting and complications following pancreatoduodenectomy for pancreatic cancer: an analysis of the ACS-NSQIP registry.
PubMed 文献 · Surg Endosc · 2020-11-25

该研究基于ACS-NSQIP登记数据,比较胰腺癌伴胆道梗阻行胰十二指肠切除术患者中,术前接受ERCP支架置入与未置入者的30天并发症风险。经倾向评分匹配后,支架组并发症发生率为55%,未支架组为53%,风险比1.04(95%CI 0.97-1.11,p=0.23),差异无统计学意义。结论认为术前ERCP支架置入未增加术后并发症风险,可安全用于缓解症状或为术前化疗创造条件。

要点

  • 术前ERCP支架置入不增加胰腺癌胰十二指肠切除术后30天并发症风险。
  • 匹配后支架组并发症55%,未支架组53%,风险比1.04(95%CI 0.97-1.11,p=0.23)。
  • 胆道支架可安全用于缓解梗阻症状或为术前化疗创造条件。

核心结论

  • 术前ERCP支架置入与胰腺癌伴梗阻性黄疸行胰十二指肠切除术患者术后并发症风险增加无关。
  • 胆道支架可安全考虑用于症状缓解和潜在辅助术前化疗。

研究设计与样本

  • 基于ACS-NSQIP登记数据库2014至2017年数据的回顾性队列分析。
  • 纳入6073例因胰腺癌伴梗阻性黄疸行胰十二指肠切除术的患者,其中92%(5564例)符合研究条件。
  • 采用倾向评分匹配平衡20项基线特征,将952例未支架患者与最多4倍术前ERCP支架置入患者(n=3467)匹配,形成4419例匹配队列。
  • 主要结局为比较两组30天并发症(复合结局)风险,使用对数二项回归模型估计风险比。

主要发现

  • 匹配队列中,术前ERCP支架置入组1901例(55%)发生术后并发症,未支架组501例(53%)发生术后并发症。
  • 风险比为1.04(95%CI 0.97-1.11,p=0.23),差异无统计学意义。

临床怎么用

  • 对于胰腺癌伴梗阻性黄疸需行胰十二指肠切除术的患者,术前ERCP支架置入不增加术后并发症风险,可安全用于缓解症状或为术前化疗创造条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Historically, pre-operative biliary stenting has been associated with higher infectious complication rates following pancreatoduodenectomy. However, alleviation of biliary obstruction is necessary for consideration of pre-operative chemotherapy, which may improve disease-free survival, or for mitigation of symptoms while awaiting surgery. Our aim is to compare contemporary post-operative complication risk among patients with pre-operative endoscopic retrograde cholangiopancreatography (ERCP) stenting compared to those without. METHODS: Patients who underwent a pancreatoduodenectomy for pancreatic cancer with biliary obstruction within the ACS-NSQIP registry from 2014 to 2017 were identified. The primary outcome was to compare the risk of 30-day complication (composite outcome) between patients with and without pre-operative ERCP stenting. Propensity score matching was used to ensure balanced baseline characteristics and log-binomial regression models were used to estimate risk ratios for overall perioperative complication between groups. RESULTS: From 6073 patients with obstructive jaundice undergoing pancreatoduodenectomy for pancreatic cancer, 92% (5564) were eligible for the study. After performing a propensity score matching on 20 baseline characteristics, 952 patients without stenting were matched to up to four patients who received pre-operative ERCP stenting (n = 3467) for a matched cohort of 4419. A total of 1901 (55%) patients with pre-operative ERCP stenting experienced a post-operative complication compared to 501 (53%) patients without stenting (risk ratio 1.04, 95% CI 0.97-1.11, p = 0.23). CONCLUSION: Pre-operative ERCP stenting was not associated with an increased risk of post-operative complication in patients undergoing pancreatoduodenectomy with obstructive jaundice. Biliary stenting may be safely considered for symptom relief and to potentially facilitate pre-operative chemotherapy for pancreatic cancer.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Garcia-Ochoa C, McArthur E, Skaro A, et al. Pre-operative stenting and complications following pancreatoduodenectomy for pancreatic cancer: an analysis of the ACS-NSQIP registry. Surg Endosc. 2020. PMID: 33237466. doi:10.1007/s00464-020-08160-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。